A phase 2 study of isatuximab monotherapy in patients with multiple myeloma who are refractory to daratumumab

Affiliations

• ¹ Translational Genomics Research Institute, City of Hope Cancer Center, Phoenix, AZ, USA.
• ² Unité Hémopathies Lymphoïdes, CHU Henri Mondor, Créteil, France.
• ³ Service d'hématologie, CHRU Hôpitaux de Brabois, Nancy, France.
• ⁴ Département d'hématologie Clinique, Centre Hospitalier Universitaire de Montpellier, Montpellier, France.
• ⁵ Hematology Department, Nantes University Hospital, Nantes, France.
• ⁶ Duke Cancer Institute, Duke University, Durham, NC, USA.
• ⁷ Department of Internal Medicine, Hematology and Oncology, University Hospital Brno, Brno, Czech Republic.
• ⁸ 1st Department of Medicine-Department of Hematology First Faculty of Medicine Charles University and General Hospital in Prague, Prague, Czech Republic.
• ⁹ Division of Medical Oncology, Washington University, St Louis, MO, USA.
• ¹⁰ Department of Oncology, Karmanos Cancer Institute, Wayne State University, Detroit, MI, USA.
• ¹¹ Department of Medicine, Bone Marrow Transplant, University of Maryland Greenebaum Cancer Center, Baltimore, MD, USA.
• ¹² Gabrail Cancer Center, Canton, OH, USA.
• ¹³ Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA.
• ¹⁴ CHU de Toulouse, IUCT-O, Université de Toulouse, UPS, Service d'hématologie, Toulouse, France.
• ¹⁵ Sanofi Global Oncology, Cambridge, MA, USA.
• ¹⁶ Sanofi Clinical Sciences and Operations, Beijing, China.
• ¹⁷ Sanofi Translational Medicine and Early Development, Paris, France.
• ¹⁸ CHU and CIC Inserm1402, Poitiers, France.
• ¹⁹ Takeda Pharmaceuticals, Cambridge, MA, USA. Xavier.LELEU@chu-poitiers.fr.